Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Knutson

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
Plos One|December 11, 2014
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin LymphomasSarah K Knutson, Natalie M Warholic, L Danielle Johnston, et al.
Molecular Cancer Therapeutics|September 5, 2024
Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in CancerRobinson Triboulet, Khikmet Sadykov, Darren M Harvey, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo ActivityJohn E Campbell, Kevin W Kuntz, Sarah K Knutson, et al.
Cancer Cell|November 16, 2010
Hdac3 is essential for the maintenance of chromatin structure and genome stabilitySrividya Bhaskara, Sarah K Knutson, Guochun Jiang, et al.
Nature Chemical Biology|October 2, 2012
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cellsSarah K Knutson, Tim J Wigle, Natalie M Warholic, et al.
Molecular Cancer Therapeutics|February 25, 2014
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphomaSarah K Knutson, Satoshi Kawano, Yukinori Minoshima, et al.
Nature Medicine|October 6, 2015
Loss of BAP1 function leads to EZH2-dependent transformationLindsay M LaFave, Wendy Béguelin, Richard Koche, et al.
Nature Medicine|June 9, 2016
Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status"Lindsay M LaFave, Wendy Béguelin, Richard Koche, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Plos One|December 11, 2014
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin LymphomasSarah K Knutson, Natalie M Warholic, L Danielle Johnston, et al.
Molecular Cancer Therapeutics|September 5, 2024
Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in CancerRobinson Triboulet, Khikmet Sadykov, Darren M Harvey, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo ActivityJohn E Campbell, Kevin W Kuntz, Sarah K Knutson, et al.
Cancer Cell|November 16, 2010
Hdac3 is essential for the maintenance of chromatin structure and genome stabilitySrividya Bhaskara, Sarah K Knutson, Guochun Jiang, et al.
Nature Chemical Biology|October 2, 2012
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cellsSarah K Knutson, Tim J Wigle, Natalie M Warholic, et al.
Molecular Cancer Therapeutics|February 25, 2014
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphomaSarah K Knutson, Satoshi Kawano, Yukinori Minoshima, et al.
Nature Medicine|October 6, 2015
Loss of BAP1 function leads to EZH2-dependent transformationLindsay M LaFave, Wendy Béguelin, Richard Koche, et al.
Nature Medicine|June 9, 2016
Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status"Lindsay M LaFave, Wendy Béguelin, Richard Koche, et al.
Pageof 10